Journal of Cardiac Failure最新文献

{"title":"The Emerging Myth of Primary Graft Dysfunction in the Era of Advanced Organ Preservation in Heart Transplantation","authors":"NICOLE K. BART MBBS, PhD , ANDREAS ZUCKERMANN MD , MANDEEP R. MEHRA MD, MSc","doi":"10.1016/j.cardfail.2025.01.013","DOIUrl":"10.1016/j.cardfail.2025.01.013","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 979-982"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Focus: How Can Food Choices Help Treat Heart Failure? An Explanation of “Medically Tailored Meals in Heart Failure: A Systematic Review of the Literature 2013–2023”","authors":"NICHOLAS S. HENDREN MD , JENNIFER T. THIBODEAU MD, MSCS","doi":"10.1016/j.cardfail.2024.11.009","DOIUrl":"10.1016/j.cardfail.2024.11.009","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 951-952"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inertia Is Not an Option: Laying the Foundation for a Consensus on the Assessment of Kidney Function in Acute Decompensated Heart Failure","authors":"ISABELLA CAVAGNA BS , MONA FIUZAT PharmD , ANURADHA LALA MD , JAMES JANUZZI MD , WILLIAM ABRAHAM MD , MATTHEW DIMOND BS , MARVIN KONSTAM MD , CHRISTOPHER O'CONNOR MD , MARIA ROSA COSTANZO MD , Heart Failure Collaboratory","doi":"10.1016/j.cardfail.2025.01.025","DOIUrl":"10.1016/j.cardfail.2025.01.025","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 953-956"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences Between Ischemic and Nonischemic Cardiomyopathy in Heart Failure Related Cardiogenic Shock","authors":"JASON FEINMAN MD ,&nbsp;MATTHEW I. TOMEY MD ,&nbsp;MICHAEL G. PALAZZOLO MS ,&nbsp;MIGUEL MARTILLO MD ,&nbsp;MARIA RONQUILLO MD ,&nbsp;NOAH MOSS MD ,&nbsp;GREGORY SERRAO MD ,&nbsp;ERIN A. BOHULA MD, DPhil ,&nbsp;DAVID D. BERG MD, MPH ,&nbsp;SEAN VAN DIEPEN MD, MSc ,&nbsp;JASON N. KATZ MD, MHS ,&nbsp;MESHE D. CHONDE MD ,&nbsp;SUNIT-PREET CHAUDHRY MD ,&nbsp;ALVIN J. GEORGE MD ,&nbsp;DANIEL GERBER MD ,&nbsp;MICHAEL J. GOLDFARB MD, MSc ,&nbsp;NORMA M. KELLER MD ,&nbsp;MICHAEL C. KONTOS MD ,&nbsp;DANIEL B. LORIAUX MD ,&nbsp;CONNOR G. O'BRIEN MD ,&nbsp;EVAN LEIBNER MD, PhD","doi":"10.1016/j.cardfail.2025.01.020","DOIUrl":"10.1016/j.cardfail.2025.01.020","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure-related cardiogenic shock (HF-CS) accounts for a growing proportion of cardiogenic shock (CS)-related admissions to contemporary cardiac intensive care units. Limited data exist comparing nonischemic (NICM) and ischemic cardiomyopathy (ICM) in this setting.</div></div><div><h3>Methods and Results</h3><div>We sought to examine the differences in patients’ characteristics, in-hospital treatments and outcomes in individuals admitted with ICM and NICM HF-CS. The study population included CS admissions within the Critical Care Cardiology Trials Network registry from 2017–2022. CS due to acute myocardial infarction or secondary causes was excluded. Admission characteristics, in-hospital treatments and outcomes were captured. The primary outcome of all-cause in-hospital mortality for ICM vs NICM was compared by using multivariable logistic regression; 2463 hospital admissions for HF-CS, including 902 (36.6%) admissions with ICM and 1561 (63.4%) admissions with NICM, were included. Patients with ICM more commonly had pre-existing comorbidities, pre-admission cardiac arrest and higher Sequential Organ Failure Assessment scores. The use of inotropes and temporary mechanical circulatory support was similar; however, the rates of mechanical ventilation and renal-replacement therapies were higher for ICM. Patients with ICM were less likely to undergo cardiac transplantation but had similar rates of durable left ventricular assist device implantation. After multivariable adjustment, patients with ICM were significantly more likely to die during the index hospitalization (OR 1.56, 95% CI 1.26–1.93; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Among patients admitted to cardiac intensive care units with HF-CS, patients with ICM were sicker, less likely to undergo cardiac transplantation, and more likely to die when compared with patients with NICM.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 961-966"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Initiation With Sacubitril/valsartan on Blood Neurodegeneration Markers in HFrEF","authors":"SURIYA PRAUSMÜLLER MD ,&nbsp;RAPHAEL WURM MD ,&nbsp;MARKUS PONLEITNER MD ,&nbsp;ELISABETH STÖGMANN MD ,&nbsp;MARTIN HÜLSMANN MD ,&nbsp;NOEMI PAVO MD, PhD","doi":"10.1016/j.cardfail.2025.01.021","DOIUrl":"10.1016/j.cardfail.2025.01.021","url":null,"abstract":"<div><h3>Background</h3><div>Sacubitril/valsartan is a key therapy for heart failure with reduced ejection fraction (HFrEF). However, concerns remain regarding its potential impact on cognitive function, because neprilysin inhibition may influence amyloid-β (Aβ) metabolism. This study evaluates the effect of sacubitril/valsartan on plasma biomarkers of neurodegeneration.</div></div><div><h3>Methods</h3><div>Plasma neuromarkers (i.e., Aβ40, Aβ42, neurofilament light chain [NfL], and total tau [t-tau]) were measured at baseline, 3 months and 1 year after sacubitril/valsartan initiation by using the single-molecule array (SIMOA) technology in a cohort with HFrEF from a prospective registry with Biobank. Comparisons were made for baseline vs 3-month and baseline vs 1-year follow-up.</div></div><div><h3>Results</h3><div>A total of 31 patients with HFrEF (median age: 61 years, 74% male, median NT-proBNP level: 2333 pg/mL) were included. Aβ40 increased transiently at 3 months (228.6 pg/mL [Q1–Q3: 157.8–321.1] vs 138.8 [110.0–202.2]; <em>P</em> &lt; 0.001) but remained unchanged at 1 year (215.0 [106.5–290.9]; <em>P</em> = 0.052). Aβ42 remained stable (9.90 [6.67–12.49] and 8.43 [5.57–11.86] vs 7.84 [6.50–11.02] pg/mL; <em>P</em> = 0.108 and 0.771), resulting in a reduced Aβ42/Aβ40 ratio at both follow-ups (0.039 [0.036–0.049] at 3 months, <em>P</em> &lt; 0.001; 0.048 [0.041–0.060] at 1 year, <em>P</em> = 0.026; vs 0.055 [0.052–0.061]). Total tau remained unchanged (1.13 [0.91–1.90] and 1.21 [0.85–1.65] vs 1.03 [0.82–1.53] pg/mL; <em>P</em> = 0.068 and 0.188), while NfL increased at 1 year (28.3 [16.5–78.6] vs 22.6 [15.1–46.9] pg/mL; <em>P</em> = 0.013), with no short-term change (25.3 [15.0–51.3]; <em>P</em> = 0.502).</div></div><div><h3>Conclusion</h3><div>Sacubitril/valsartan therapy in patients with HFrEF leads to a transient increase in Aβ40 and a sustained reduction in the Aβ42/Aβ40 ratio. Stable t-tau and short-term stable NfL levels provide reassurance regarding the absence of immediate neuronal injury, while an NfL increase observed at 1 year may indicate ongoing progression of heart failure rather than direct neurotoxicity. These findings highlight the need for cautious interpretation of the Aβ42/Aβ40 ratio in neurocognitive assessments among patients treated with angiotensin receptor-neprilysin inhibitors. Further studies are warranted to clarify the long-term cognitive implications of sacubitril/valsartan in patients with HFrEF.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 967-971"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HFSA Annual Scientific Meeting 2025: Where Heart Failure Teams Gather!","authors":"","doi":"10.1016/j.cardfail.2025.05.008","DOIUrl":"10.1016/j.cardfail.2025.05.008","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 983-986"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144240235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial","authors":"ANDREW WANG MD ,&nbsp;NEAL K. LAKDAWALA MD ,&nbsp;THEODORE P. ABRAHAM MD ,&nbsp;ESTER KIM NILLES PhD ,&nbsp;DANIEL M. WOJDYLA MS ,&nbsp;ANJALI TIKU OWENS MD ,&nbsp;RICHARD G. BACH MD ,&nbsp;SARA SABERI MD ,&nbsp;AMY SEHNERT MD ,&nbsp;SHARON CRESCI MD","doi":"10.1016/j.cardfail.2024.10.449","DOIUrl":"10.1016/j.cardfail.2024.10.449","url":null,"abstract":"<div><h3>Background and Aims</h3><div>In patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM), it is unclear if response to cardiac myosin inhibition varies with older age or a longer duration of diagnosis. This study evaluated the response of these subgroups to mavacamten therapy for all primary, secondary and exploratory endpoints in the EXPLORER-HCM trial (ClinicalTrials.gov: NCT03470545).</div></div><div><h3>Methods</h3><div>Patients were stratified by age (≤ 60 vs &gt; 60 years) and duration of HCM diagnosis (≤ 5 vs &gt; 5 years). To estimate treatment differences and evaluate age and diagnosis duration by treatment interaction, analysis of covariance was used to model changes in continuous endpoints, and a generalized linear model was used for binary endpoints.</div></div><div><h3>Results</h3><div>Older patients were more commonly female (53% vs 29%), had lower prevalences of pathogenic/likely pathogenic HCM gene variants (17% vs 36%), lower mean peak oxygen consumption (pVO₂) (17.6 vs 21.1 mL/kg/min), and higher mean NT-proBNP levels (817 vs 592 ng/L) but similar NYHA classes and quality-of-life scores. Patients with longer vs shorter diagnosis duration had similar mean ages (59.0 ± 11.6 vs 57.9 ± 12.3 years) but more family histories of HCM (38% vs 16%) and higher mean NT-pro BNP levels (938 ± 118 vs 494 ± 145 ng/mL). No differences were observed in improvement in peak oxygen consumption, NYHA class or patient-reported outcomes among older patients and those with longer durations of diagnosis.</div></div><div><h3>Conclusions</h3><div>In EXPLORER-HCM, mavacamten treatment had a similar benefit for all primary, secondary and exploratory endpoints in patients with symptomatic, obstructive HCM, regardless of age or duration of diagnosis.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 901-911"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving the Assessment of Left Ventricular Diastolic Dysfunction by Including Left Atrial Strain in the Algorithm","authors":"LIN WANG MD, MS ,&nbsp;JONATHAN WEBER MPH ,&nbsp;JASON CRAFT MD ,&nbsp;MICHAEL PASSICK RCDS, MBA ,&nbsp;OMAR K. KHALIQUE MD ,&nbsp;ZIAD A. ALI MD, DPhil ,&nbsp;JAE K. OH MD ,&nbsp;J. JANE CAO MD, MPH","doi":"10.1016/j.cardfail.2024.08.064","DOIUrl":"10.1016/j.cardfail.2024.08.064","url":null,"abstract":"<div><h3>Background</h3><div>The latest guidelines on echocardiographic assessment of left ventricular diastolic dysfunction (LVDD) leave a significant proportion of patients with LVDD status undetermined. We aimed to examine the implication of an alternative algorithm incorporating left atrial (LA) strain as a tiebreaker on the indeterminate LVDD category.</div></div><div><h3>Methods and Results</h3><div>We included 823 patients who underwent echocardiography and cardiac magnetic resonance within 7 days. LVDD was assessed by echocardiography following contemporary guidelines and an alternative algorithm including LA reservoir strain as a tie breaker. LVDD was examined for its association with LV myocardial scar burden by cardiac magnetic resonance, and a composite outcome. There were 275 patients (33%) who had LVDD, of whom 119 had advanced grades of LVDD (grades II–III), and 117 (14%) had an indeterminate LVDD grade. When LA strain was applied at cutpoints of 18%, 24%, and 35%, patients were reclassified as normal or LVDD-dependent accordingly. Reclassification allowed a similar outcome risk stratification as the current guidelines.</div></div><div><h3>Conclusions</h3><div>LA reservoir strain improved LVDD assessment by eliminating indeterminate status/grade while maintaining the same effective outcome stratification as the current guidelines.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 892-900"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Noninferiority in Terms of 6-month Morbidity and Mortality Rates of a Hospital-at-home Care Pathway for Patients With Acute Heart Failure: FIL-EAS-ic Study Protocol","authors":"JEAN-MICHEL TARTIÈRE MD ,&nbsp;JOCELYNE CANDEL ,&nbsp;MATHILDE LE CAIGNEC ,&nbsp;LOLITA JAUNAY MD ,&nbsp;CHARLOTTE PATIN MD ,&nbsp;LAMIA KESRI-TARTIÈRE MD ,&nbsp;MARJORIE ESTEVENY ,&nbsp;MÉLANIE HAREL ,&nbsp;HANNAH DERKSEN MD ,&nbsp;GONZALO QUAINO MD ,&nbsp;ISABELLE LECARDONNEL MD ,&nbsp;FARID CHALLAL MD ,&nbsp;PAULINE ARMANGAUD ,&nbsp;CAROLINE BIRGY MD","doi":"10.1016/j.cardfail.2024.09.016","DOIUrl":"10.1016/j.cardfail.2024.09.016","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure (HF) is a common cause of hospitalization and is associated with high mortality rates, long hospital stays and high economic costs worldwide. Novel care pathways are increasingly being considered to address these burdens. In France, a mixed conventional hospitalization and hospital-at-home (HaH) care pathway (named FIL-EAS-ic) has been designed to reduce hospital lengths of stay without impairing HF outcomes. This protocol describes the study design, which evaluate the noninferiority of the FIL-EAS-ic pathway compared to conventional hospitalization in terms of 6-month all-cause mortality and/or unscheduled HF-related hospitalization.</div></div><div><h3>Methods and Results</h3><div>A randomized, prospective multicenter trial (NCT04878263) will be conducted involving 2 groups of patients in a 1:2 ratio: (1) a control group following the conventional hospitalization pathway; and (2) the experimental group following the FIL-EAS-ic pathway. We aim to include 454 patients from the <em>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</em> and the <em>Hôpital d'Instruction des Armées Sainte-Anne</em> in France from June 2021–June 2023. The noninferiority of the FIL-EAS-ic pathway compared to conventional hospitalization, in terms of 6-month all-cause mortality and/or unscheduled HF-related hospitalization, will be tested by the Farrington-Manning method. Impact on treatment adherence, HF rehospitalizations and cumulative time spent in the hospital will also be compared between the 2 groups.</div></div><div><h3>Conclusions</h3><div>This clinical trial will provide evidence concerning a novel HF care pathway in France as well as its potential to improve follow-up care, quality of life, and patient satisfaction and its potential to reduce costs.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 928-938"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry","authors":"STEPHEN J. GREENE MD ,&nbsp;MICHAEL BÖHM MD ,&nbsp;BIYKEM BOZKURT MD, PhD ,&nbsp;JAVED BUTLER MD, MPH, MBA ,&nbsp;JOHN G.F. CLELAND MD, PhD ,&nbsp;ANDREW J.S. COATS MD ,&nbsp;NIHAR R. DESAI MD, MPH ,&nbsp;DIEDERICK E. GROBBEE MD, PhD ,&nbsp;ELLIE KELEPOURIS MD ,&nbsp;FAUSTO PINTO MD, PhD ,&nbsp;GIUSEPPE ROSANO MD, PhD ,&nbsp;ISABELLE MORIN MSc ,&nbsp;PETER SZECSÖDY MD ,&nbsp;SOLENN FABIEN PharmD ,&nbsp;SANDRA WAECHTER PhD ,&nbsp;MARIA G. CRESPO-LEIRO MD, PhD ,&nbsp;MARTIN HÜLSMANN MD ,&nbsp;TIBOR KEMPF MD ,&nbsp;OTMAR PFISTER MD ,&nbsp;ANNE-CATHERINE POULEUR MD, PhD ,&nbsp;MIKHAIL N. KOSIBOROD MD","doi":"10.1016/j.cardfail.2024.08.048","DOIUrl":"10.1016/j.cardfail.2024.08.048","url":null,"abstract":"<div><h3>Background</h3><div>Despite guideline recommendations, many patients with heart failure (HF) do not receive target dosages of renin-angiotensin-aldosterone system inhibitors (RAASis) in clinical practice due, in part, to concerns about hyperkalemia (HK).</div></div><div><h3>Methods and Results</h3><div>This noninterventional, multinational, multicenter registry (NCT04864795; 111 sites in Europe and the USA) enrolled 2558 eligible adults with chronic HF (mostly with reduced ejection fraction [HFrEF]). Eligibility criteria included use of angiotensin-converting-enzyme inhibitor/angiotensin-II receptor blocker/angiotensin-receptor-neprilysin inhibitor, being a candidate for or treatment with a mineralocorticoid receptor antagonist, and increased risk of HK (eg, current serum potassium &gt; 5.0 mmol/L), history of HK in the previous 24 months, or estimated glomerular filtration rate &lt; 45 mL/min/1.73 m²). Information on RAASi and other guideline-recommended therapies was collected retrospectively and prospectively (≥ 6 months). Patients were followed according to local clinical practice, without study-specific visits or interventions. The main objectives were to characterize RAASi treatment patterns compared with guideline recommendations, describe RAASi modifications following episodes of HK, and describe RAASi treatment in patients treated with patiromer. Baseline characteristics for the first 1000 patients are presented.</div></div><div><h3>Conclusions</h3><div>CARE-HK is a multinational prospective HF registry designed to report on the management and outcomes of patients with HF at high risk for HK in routine clinical practice.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 6","pages":"Pages 881-891"},"PeriodicalIF":6.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}